196 related articles for article (PubMed ID: 27392855)
41. Does an Alzheimer's disease susceptibility gene influence the cognitive effects of cancer therapy?
Caselli RJ
Pediatr Blood Cancer; 2014 Oct; 61(10):1739-42. PubMed ID: 24106134
[TBL] [Abstract][Full Text] [Related]
42. Does taking statins affect the pathological burden in autopsy-confirmed Alzheimer's dementia?
Crum J; Wilson J; Sabbagh M
Alzheimers Res Ther; 2018 Oct; 10(1):104. PubMed ID: 30285877
[TBL] [Abstract][Full Text] [Related]
43. Neuropathologic, genetic, and longitudinal cognitive profiles in primary age-related tauopathy (PART) and Alzheimer's disease.
Bell WR; An Y; Kageyama Y; English C; Rudow GL; Pletnikova O; Thambisetty M; O'Brien R; Moghekar AR; Albert MS; Rabins PV; Resnick SM; Troncoso JC
Alzheimers Dement; 2019 Jan; 15(1):8-16. PubMed ID: 30465754
[TBL] [Abstract][Full Text] [Related]
44. Effects of APOE-ε4 allele load on brain morphology in a cohort of middle-aged healthy individuals with enriched genetic risk for Alzheimer's disease.
Cacciaglia R; Molinuevo JL; Falcón C; Brugulat-Serrat A; Sánchez-Benavides G; Gramunt N; Esteller M; Morán S; Minguillón C; Fauria K; Gispert JD;
Alzheimers Dement; 2018 Jul; 14(7):902-912. PubMed ID: 29605385
[TBL] [Abstract][Full Text] [Related]
45. Healthy versus Entorhinal Cortical Atrophy Identification in Asymptomatic APOE4 Carriers at Risk for Alzheimer's Disease.
Konishi K; Joober R; Poirier J; MacDonald K; Chakravarty M; Patel R; Breitner J; Bohbot VD
J Alzheimers Dis; 2018; 61(4):1493-1507. PubMed ID: 29278888
[TBL] [Abstract][Full Text] [Related]
46. Association between Cerebrospinal Fluid Biomarkers for Alzheimer's Disease, APOE Genotypes and Auditory Verbal Learning Task in Subjective Cognitive Decline, Mild Cognitive Impairment, and Alzheimer's Disease.
Mandecka M; Budziszewska M; Barczak A; Pepłońska B; Chodakowska-Żebrowska M; Filipek-Gliszczyńska A; Nesteruk M; Styczyńska M; Barcikowska M; Gabryelewicz T
J Alzheimers Dis; 2016 Jul; 54(1):157-68. PubMed ID: 27472875
[TBL] [Abstract][Full Text] [Related]
47. [Expression of apolipoprotein E in Alzheimer's disease and its significance].
He SR; Liu DG; Wang S; Xia YJ
Zhonghua Bing Li Xue Za Zhi; 2005 Sep; 34(9):556-60. PubMed ID: 16468304
[TBL] [Abstract][Full Text] [Related]
48. APOE epsilon 4 influences the pathological phenotype of Alzheimer's disease by favouring cerebrovascular over parenchymal accumulation of A beta protein.
Chalmers K; Wilcock GK; Love S
Neuropathol Appl Neurobiol; 2003 Jun; 29(3):231-8. PubMed ID: 12787320
[TBL] [Abstract][Full Text] [Related]
49. Subjective Cognitive Decline and APOE ɛ4: A Systematic Review.
Ali JI; Smart CM; Gawryluk JR
J Alzheimers Dis; 2018; 65(1):303-320. PubMed ID: 30040718
[TBL] [Abstract][Full Text] [Related]
50. Impact of APOE genotype on neuropathologic and neurochemical markers of Alzheimer disease.
Tiraboschi P; Hansen LA; Masliah E; Alford M; Thal LJ; Corey-Bloom J
Neurology; 2004 Jun; 62(11):1977-83. PubMed ID: 15184600
[TBL] [Abstract][Full Text] [Related]
51. Longitudinal Changes in Serum Glucose Levels are Associated with Metabolic Changes in Alzheimer's Disease Related Brain Regions.
Burns CM; Kaszniak AW; Chen K; Lee W; Bandy DJ; Caselli RJ; Reiman EM
J Alzheimers Dis; 2018; 62(2):833-840. PubMed ID: 29480176
[TBL] [Abstract][Full Text] [Related]
52. Prediction models for dementia and neuropathology in the oldest old: the Vantaa 85+ cohort study.
Hall A; Pekkala T; Polvikoski T; van Gils M; Kivipelto M; Lötjönen J; Mattila J; Kero M; Myllykangas L; Mäkelä M; Oinas M; Paetau A; Soininen H; Tanskanen M; Solomon A
Alzheimers Res Ther; 2019 Jan; 11(1):11. PubMed ID: 30670070
[TBL] [Abstract][Full Text] [Related]
53. Epidemiological, clinical, and neuropathological study of apolipoprotein E genotype in Alzheimer's disease.
Hyman BT; Gomez-Isla T; Rebeck GW; Briggs M; Chung H; West HL; Greenberg S; Mui S; Nichols S; Wallace R; Growdon JH
Ann N Y Acad Sci; 1996 Dec; 802():1-5. PubMed ID: 8993478
[TBL] [Abstract][Full Text] [Related]
54. Association between severe cerebral amyloid angiopathy and cerebrovascular lesions in Alzheimer disease is not a spurious one attributable to apolipoprotein E4.
Olichney JM; Hansen LA; Hofstetter CR; Lee JH; Katzman R; Thal LJ
Arch Neurol; 2000 Jun; 57(6):869-74. PubMed ID: 10867785
[TBL] [Abstract][Full Text] [Related]
55. The Effect of the APOE Genotype on Individual BrainAGE in Normal Aging, Mild Cognitive Impairment, and Alzheimer's Disease.
Löwe LC; Gaser C; Franke K;
PLoS One; 2016; 11(7):e0157514. PubMed ID: 27410431
[TBL] [Abstract][Full Text] [Related]
56. APOE in the normal brain.
Flowers SA; Rebeck GW
Neurobiol Dis; 2020 Mar; 136():104724. PubMed ID: 31911114
[TBL] [Abstract][Full Text] [Related]
57. Influence of the apolipoprotein E genotype on amyloid deposition and neurofibrillary tangle formation in Alzheimer's disease.
Nagy Z; Esiri MM; Jobst KA; Johnston C; Litchfield S; Sim E; Smith AD
Neuroscience; 1995 Dec; 69(3):757-61. PubMed ID: 8596645
[TBL] [Abstract][Full Text] [Related]
58. Association of Cerebrospinal Fluid (CSF) Insulin with Cognitive Performance and CSF Biomarkers of Alzheimer's Disease.
Geijselaers SLC; Aalten P; Ramakers IHGB; De Deyn PP; Heijboer AC; Koek HL; OldeRikkert MGM; Papma JM; Reesink FE; Smits LL; Stehouwer CDA; Teunissen CE; Verhey FRJ; van der Flier WM; Biessels GJ;
J Alzheimers Dis; 2018; 61(1):309-320. PubMed ID: 29154275
[TBL] [Abstract][Full Text] [Related]
59. Association between APOE genotype, neuropathology and dementia in the older population of England and Wales.
Nicoll JA; Savva GM; Stewart J; Matthews FE; Brayne C; Ince P;
Neuropathol Appl Neurobiol; 2011 Apr; 37(3):285-94. PubMed ID: 20880354
[TBL] [Abstract][Full Text] [Related]
60. Apolipoprotein E-epsilon4 alleles in cerebral amyloid angiopathy and cerebrovascular pathology associated with Alzheimer's disease.
Premkumar DR; Cohen DL; Hedera P; Friedland RP; Kalaria RN
Am J Pathol; 1996 Jun; 148(6):2083-95. PubMed ID: 8669492
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
